Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
Imagine if we could use machine learning to enhance the care we deliver, analyzing a larger body of patient-specific factors in order to make more reliable predictions of risk for perinatal mood and anxiety disorders.
TMS in pregnancy and the postpartum period appears to be a promising treatment option with no reports of adverse obstetric outcomes or congenital malformations.
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
Fathers may also suffer from perinatal depression and paternal depression, just like maternal depression, can have negative effects.
Cannabis use, as well as use of benzodiazepines and sedative-hypnotic medications, was more common in women with depression.
Fetal brain development is altered by elevated maternal distress and has adverse infant social-emotional and cognitive outcomes.
Intravenous ketamine at delivery reduced risk for postpartum depression; however, only in women at high risk for PPD.
We are now recruiting for a study using a novel app using behavioral activation to treat depression during pregnancy.
In terms of the efficacy of bright light therapy for depression during pregnancy, the jury is still out.Â
